PCV73 COST-EFFECTIVENESS OF RIVAROXABAN VERSUS WARFARIN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION IN THE JAPANESE HEALTHCARE SETTING

Autor:	Rei Goto, G. Kiyabu, J. Dorey, Sayako Akiyama, M. Hori, N. Tanahashi
Rok vydání:	2019
Předmět:	Rivaroxaban medicine.medical_specialty business.industry Cost effectiveness Health Policy Public Health Environmental and Occupational Health Non valvular atrial fibrillation Warfarin Stroke prevention Health care Emergency medicine medicine business medicine.drug
Zdroj:	Value in Health. 22:S554-S555
ISSN:	1098-3015
DOI:	10.1016/j.jval.2019.09.798
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::e39d9449b4d37db63ffee6a6ff08f39c https://doi.org/10.1016/j.jval.2019.09.798 Zobrazit plný text záznamu Full Text from ScienceDirect